{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:21:09Z","timestamp":1788524469780,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["Grant No: BT\/PR27126\/MED\/30\/1943\/2017"],"award-info":[{"award-number":["Grant No: BT\/PR27126\/MED\/30\/1943\/2017"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001502","name":"Department of Atomic Energy, Government of India","doi-asserted-by":"publisher","award":["Grant No: 1\/3(7)\/2020\/TMC\/R&D-II\/8823 Dt.30.07.2021"],"award-info":[{"award-number":["Grant No: 1\/3(7)\/2020\/TMC\/R&D-II\/8823 Dt.30.07.2021"]}],"id":[{"id":"10.13039\/501100001502","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02171-1","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:54:57Z","timestamp":1782179697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alpelisib enhances cisplatin mediated cytotoxicity in non-mutated, PIK3CA-dependent high-grade serous ovarian cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Megha","family":"Mehrotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elveera","family":"Saldanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diksha","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Dhadve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Sakpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Chandrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritha","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"7","key":"2171_CR1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/bjc.2012.376","volume":"107","author":"J Borley","year":"2012","unstructured":"Borley J, et al. Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer. 2012;107(7):1069\u201374.","journal-title":"Br J Cancer"},{"issue":"1","key":"2171_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"Cancer J Clin"},{"issue":"6","key":"2171_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"Bast RC Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415\u201328.","journal-title":"Nat Rev Cancer"},{"key":"2171_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11912-006-0074-9","volume":"8","author":"TJ Herzog","year":"2006","unstructured":"Herzog TJ. The current treatment of recurrent ovarian cancer. Curr Oncol Rep. 2006;8:448\u201354.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"2171_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","volume":"21","author":"GC Stuart","year":"2011","unstructured":"Stuart GC et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21(4):750-5.","journal-title":"Int J Gynecol Cancer"},{"key":"2171_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-031-58311-7_4","volume":"1452","author":"M Mehrotra","year":"2024","unstructured":"Mehrotra M, et al. Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives. Adv Exp Med Biol. 2024;1452:65\u201396.","journal-title":"Adv Exp Med Biol"},{"issue":"19","key":"2171_CR7","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","volume":"29","author":"A Dilawari","year":"2023","unstructured":"Dilawari A, et al. FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer. Clin Cancer Res. 2023;29(19):3835\u201340.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2171_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13048-019-0579-0","volume":"12","author":"S Gupta","year":"2019","unstructured":"Gupta S, et al. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives \u2013 a review. J Ovarian Res. 2019;12(1):103.","journal-title":"J Ovarian Res"},{"issue":"6","key":"2171_CR9","doi-asserted-by":"publisher","first-page":"102041","DOI":"10.1016\/j.esmoop.2023.102041","volume":"8","author":"S Joris","year":"2023","unstructured":"Joris S, et al. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. ESMO Open. 2023;8(6):102041.","journal-title":"ESMO Open"},{"issue":"7353","key":"2171_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell D, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature"},{"issue":"8","key":"2171_CR11","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/ijc.21461","volume":"118","author":"BI Bertelsen","year":"2006","unstructured":"Bertelsen BI, et al. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer. 2006;118(8):1877\u201383.","journal-title":"Int J Cancer"},{"issue":"6","key":"2171_CR12","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3892\/or.2012.2041","volume":"28","author":"JC Hahne","year":"2012","unstructured":"Hahne JC, et al. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. Oncol Rep. 2012;28(6):2023\u20138.","journal-title":"Oncol Rep"},{"issue":"4","key":"2171_CR13","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1210\/en.2005-1450","volume":"147","author":"T Ohta","year":"2006","unstructured":"Ohta T, et al. Inhibition of Phosphatidylinositol 3-Kinase Increases Efficacy of Cisplatin in in Vivo Ovarian Cancer Models. Endocrinology. 2006;147(4):1761\u20139.","journal-title":"Endocrinology"},{"issue":"11","key":"2171_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2014;370(11):997\u20131007.","journal-title":"N Engl J Med"},{"issue":"20","key":"2171_CR15","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929\u201340.","journal-title":"N Engl J Med"},{"issue":"5","key":"2171_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","volume":"13","author":"C Fritsch","year":"2014","unstructured":"Fritsch C, et al. Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014;13(5):1117\u201329.","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"2171_CR17","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1200\/JCO-25-00225","volume":"43","author":"PA Konstantinopoulos","year":"2025","unstructured":"Konstantinopoulos PA, et al. Primary Analysis of EPIK-O\/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. J Clin Oncol. 2025;43(26):2908\u201317.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2171_CR18","doi-asserted-by":"publisher","first-page":"e4310","DOI":"10.21769\/BioProtoc.4310","volume":"12","author":"PS Shenoy","year":"2022","unstructured":"Shenoy PS, et al. Developing Clinically Relevant Acquired Chemoresistance Models in Epithelial Ovarian Cancer Cell Lines. Bio Protoc. 2022;12(3):e4310.","journal-title":"Bio Protoc"},{"issue":"2","key":"2171_CR19","doi-asserted-by":"publisher","first-page":"e55971","DOI":"10.1371\/journal.pone.0055971","volume":"8","author":"SM Gaikwad","year":"2013","unstructured":"Gaikwad SM, et al. Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models. PLoS ONE. 2013;8(2):e55971.","journal-title":"PLoS ONE"},{"issue":"1","key":"2171_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13046-024-03147-z","volume":"43","author":"P Phadte","year":"2024","unstructured":"Phadte P, et al. Autophagy-mediated ID1 turnover dictates chemo-resistant fate in ovarian cancer stem cells. J Exp Clin Cancer Res. 2024;43(1):222.","journal-title":"J Exp Clin Cancer Res"},{"key":"2171_CR21","unstructured":"Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. Available online at: http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc."},{"issue":"15","key":"2171_CR22","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"issue":"14","key":"2171_CR23","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics. 2009;25(14):1754\u201360.","journal-title":"Bioinformatics"},{"issue":"9","key":"2171_CR24","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"issue":"1110","key":"2171_CR25","first-page":"p11101","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera GA, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinf. 2013;43(1110):p11101\u2013111033.","journal-title":"Curr Protoc Bioinf"},{"issue":"1","key":"2171_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13073-020-00803-9","volume":"12","author":"X Liu","year":"2020","unstructured":"Liu X, et al. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med. 2020;12(1):103.","journal-title":"Genome Med"},{"key":"2171_CR27","doi-asserted-by":"crossref","unstructured":"Zuguang Gu, Roland Eils, Matthias Schlesner. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847\u20139.","DOI":"10.1093\/bioinformatics\/btw313"},{"issue":"16","key":"2171_CR28","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics. 2009;25(16):2078\u20139.","journal-title":"Bioinformatics"},{"issue":"17","key":"2171_CR29","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/bioinformatics\/btp373","volume":"25","author":"DC Koboldt","year":"2009","unstructured":"Koboldt DC, et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics. 2009;25(17):2283\u20135.","journal-title":"Bioinformatics"},{"issue":"16","key":"2171_CR30","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.","journal-title":"Nucleic Acids Res"},{"key":"2171_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.biocel.2015.02.001","volume":"61","author":"SM Gaikwad","year":"2015","unstructured":"Gaikwad SM, et al. Differential activation of NF-\u03baB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells. Int J Biochem Cell Biol. 2015;61:90\u2013102.","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"2171_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/bioinformatics\/18.2.333","volume":"18","author":"X Messeguer","year":"2002","unstructured":"Messeguer X, et al. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002;18(2):333\u20134.","journal-title":"Bioinformatics"},{"key":"2171_CR33","doi-asserted-by":"crossref","unstructured":"Dhadve AC et al. Decoding molecular interplay between RUNX1 and FOXO3a underlying the pulsatile IGF1R expression during acquirement of chemoresistance. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2020;1866(6):165754.","DOI":"10.1016\/j.bbadis.2020.165754"},{"issue":"1","key":"2171_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12920-021-01017-7","volume":"14","author":"JI Davila","year":"2021","unstructured":"Davila JI, et al. Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing. BMC Med Genomics. 2021;14(1):165.","journal-title":"BMC Med Genomics"},{"issue":"2","key":"2171_CR35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/path.4185","volume":"230","author":"S Briggs","year":"2013","unstructured":"Briggs S, Tomlinson I. Germline and somatic polymerase \u03b5 and \u03b4 mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol. 2013;230(2):148\u201353.","journal-title":"J Pathol"},{"issue":"10","key":"2171_CR36","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1002\/cam4.2344","volume":"8","author":"H Hino","year":"2019","unstructured":"Hino H, et al. Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene. Cancer Med. 2019;8(10):4587\u201397.","journal-title":"Cancer Med"},{"issue":"Suppl 2","key":"2171_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12920-019-0484-9","volume":"12","author":"EN Voropaeva","year":"2019","unstructured":"Voropaeva EN, et al. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma. BMC Med Genomics. 2019;12(Suppl 2):35.","journal-title":"BMC Med Genomics"},{"issue":"8","key":"2171_CR38","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41587-023-01949-8","volume":"42","author":"HS Kim","year":"2024","unstructured":"Kim HS, et al. Direct measurement of engineered cancer mutations and their transcriptional phenotypes in single cells. Nat Biotechnol. 2024;42(8):1254\u201362.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2171_CR39","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1158\/0008-5472.CAN-08-3426","volume":"69","author":"H Holstege","year":"2009","unstructured":"Holstege H, et al. High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer. Cancer Res. 2009;69(8):3625\u201333.","journal-title":"Cancer Res"},{"issue":"6","key":"2171_CR40","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/humu.22552","volume":"35","author":"B Leroy","year":"2014","unstructured":"Leroy B, Anderson M, Soussi T. TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. Hum Mutat. 2014;35(6):672\u201388.","journal-title":"Hum Mutat"},{"issue":"Pt 5","key":"2171_CR41","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1242\/jcs.013029","volume":"121","author":"A Astanehe","year":"2008","unstructured":"Astanehe A, et al. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci. 2008;121(Pt 5):664\u201374.","journal-title":"J Cell Sci"},{"issue":"8","key":"2171_CR42","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1101\/gad.973602","volume":"16","author":"B Singh","year":"2002","unstructured":"Singh B, et al. 53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 2002;16(8):984\u201393.","journal-title":"Genes Dev"},{"issue":"30","key":"2171_CR43","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1200\/JCO.20.01924","volume":"38","author":"WP Tew","year":"2020","unstructured":"Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(30):3468\u201393.","journal-title":"J Clin Oncol"},{"key":"2171_CR44","doi-asserted-by":"publisher","first-page":"568786","DOI":"10.3389\/fonc.2020.568786","volume":"10","author":"MSN Kadri","year":"2020","unstructured":"Kadri MSN, et al. Mutational Landscape for Indian Hereditary Breast and Ovarian Cancer Cohort Suggests Need for Identifying Population Specific Genes and Biomarkers for Screening. Front Oncol. 2020;10:568786.","journal-title":"Front Oncol"},{"issue":"6","key":"2171_CR45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/jhg.2016.4","volume":"61","author":"AU Mannan","year":"2016","unstructured":"Mannan AU, et al. Detection of high frequency of mutations in a breast and\/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India. J Hum Genet. 2016;61(6):515\u201322.","journal-title":"J Hum Genet"},{"issue":"13","key":"2171_CR46","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","volume":"23","author":"P Furet","year":"2013","unstructured":"Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013;23(13):3741\u20138.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"2171_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4161\/cbt.8.1.7209","volume":"8","author":"IK Kolasa","year":"2009","unstructured":"Kolasa IK, et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther. 2009;8(1):21\u20136.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2171_CR48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ygyno.2004.11.051","volume":"97","author":"S Lee","year":"2005","unstructured":"Lee S, et al. Activation of PI3K\/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005;97(1):26\u201334.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2171_CR49","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ygyno.2012.12.019","volume":"128","author":"JB McIntyre","year":"2013","unstructured":"McIntyre JB, et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 2013;128(3):409\u201314.","journal-title":"Gynecol Oncol"},{"issue":"50","key":"2171_CR50","doi-asserted-by":"publisher","first-page":"82424","DOI":"10.18632\/oncotarget.10955","volume":"7","author":"W Arjumand","year":"2016","unstructured":"Arjumand W, et al. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells. Oncotarget. 2016;7(50):82424\u201339.","journal-title":"Oncotarget"},{"issue":"1","key":"2171_CR51","doi-asserted-by":"publisher","first-page":"12308","DOI":"10.1038\/s41598-020-68998-w","volume":"10","author":"KJ Kim","year":"2020","unstructured":"Kim KJ, et al. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. Sci Rep. 2020;10(1):12308.","journal-title":"Sci Rep"},{"issue":"1","key":"2171_CR52","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13046-017-0636-8","volume":"36","author":"B Thakur","year":"2017","unstructured":"Thakur B, Ray P. Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-\u03baB-TNF\u03b1-PIK3CA loop. J Experimental Clin Cancer Res. 2017;36(1):164.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"1","key":"2171_CR53","first-page":"930710","volume":"2012","author":"KM Jacobs","year":"2012","unstructured":"Jacobs KM, et al. GSK-3\u03b2: A Bifunctional Role in Cell Death Pathways. Int J Cell Biology. 2012;2012(1):930710.","journal-title":"Int J Cell Biology"},{"issue":"4","key":"2171_CR54","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pneurobio.2006.07.006","volume":"79","author":"E Beurel","year":"2006","unstructured":"Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol. 2006;79(4):173\u201389.","journal-title":"Prog Neurobiol"},{"key":"2171_CR55","doi-asserted-by":"publisher","unstructured":"Gunaratna, RT, et al. Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model. Oncogene. 2019;38(18):3535\u201350. https:\/\/doi.org\/10.1038\/s41388-018-0630-4.","DOI":"10.1038\/s41388-018-0630-4"},{"key":"2171_CR56","doi-asserted-by":"publisher","unstructured":"Toulany M, et al. Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res. 2012;10(7):945\u201357. https:\/\/doi.org\/10.1158\/1541-7786.MCR-11-0592.","DOI":"10.1158\/1541-7786.MCR-11-0592"},{"key":"2171_CR57","doi-asserted-by":"crossref","unstructured":"Mueck K, et al. Akt1 stimulates homologous recombination repair of DNA double-strand breaks in a Rad51-dependent manner. Int J Mol Sci. 2017;18(11).","DOI":"10.3390\/ijms18112473"},{"key":"2171_CR58","doi-asserted-by":"crossref","unstructured":"Tang J, et al. SOX2 recruits KLF4 to regulate nasopharyngeal carcinoma proliferation via PI3K\/AKT signaling. Oncogenesis. 2018;7(8):61.","DOI":"10.1038\/s41389-018-0074-2"},{"key":"2171_CR59","doi-asserted-by":"crossref","unstructured":"Mehta GA, et al. SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2. npj Breast Cancer. 2021;7(1):40.","DOI":"10.1038\/s41523-021-00248-2"},{"key":"2171_CR60","doi-asserted-by":"crossref","unstructured":"Yu B, et al. DDX55 promotes hepatocellular carcinoma progression by interacting with BRD4 and participating in exosome-mediated cell-cell communication. Cancer Sci. 2022;113(9):3002\u201317.","DOI":"10.1111\/cas.15393"},{"key":"2171_CR61","doi-asserted-by":"crossref","unstructured":"Yang N, et al. Transcriptional regulation of PIK3CA oncogene by NF-\u03baB in ovarian cancer microenvironment. PLOS ONE. 2008;3(3):e1758.","DOI":"10.1371\/journal.pone.0001758"},{"key":"2171_CR62","doi-asserted-by":"crossref","unstructured":"Astanehe A, et al. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene. 2009;28(25):2406\u201318.","DOI":"10.1038\/onc.2009.81"},{"key":"2171_CR63","doi-asserted-by":"crossref","unstructured":"Wang, Z., et al., PIK3CA Is Regulated by CUX1, Promotes Cell Growth and Metastasis in Bladder Cancer via Activating Epithelial-Mesenchymal Transition. Front Oncol. 2020;10.","DOI":"10.3389\/fonc.2020.536072"},{"key":"2171_CR64","doi-asserted-by":"crossref","unstructured":"Kennedy MC, Lowe SW. Mutant p53: it\u2019s not all one and the same. Cell Death Differ. 2022;29(5):983\u20137.","DOI":"10.1038\/s41418-022-00989-y"},{"key":"2171_CR65","doi-asserted-by":"crossref","unstructured":"Walerych D, Lisek K, Del Sal G. Mutant p53: One, No One, and One Hundred Thousand. Front Oncol. 2015.","DOI":"10.3389\/fonc.2015.00289"},{"key":"2171_CR66","doi-asserted-by":"crossref","unstructured":"Weisz L, et al. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res. 2007;67(6):2396\u2013401.","DOI":"10.1158\/0008-5472.CAN-06-2425"},{"key":"2171_CR67","doi-asserted-by":"crossref","unstructured":"Cooks T, et al. Mutant p53 prolongs NF-\u03baB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23(5):634\u201346.","DOI":"10.1016\/j.ccr.2013.03.022"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02171-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02171-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02171-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:03:06Z","timestamp":1788523386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02171-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2171"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02171-1","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Ethics Committee of ACTREC-TMC (IEC#900513), in compliance to the guidelines provided by the Declaration of Helsinki. Written informed consent was taken from all the patients from whom the samples were collected in this study.All the animal studies were performed per the approval of the Institutional Animal Ethics Committee of ACTREC (IAEC#26\/2020). The animals used in the study were provided by the Animal House Facility of ACTREC-TMC.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"279"}}